DEA Telemedicine Prescribing Flexibilities End December 31: What Florida Prescribers and Telehealth Platforms Face Before the Special Registration Rule

If you prescribe Schedule II through V controlled substances to patients you have never examined in person, you are doing it today under a temporary exception that ends on December 31, 2026. The permanent replacement, a DEA special registration rule, has been written but not published. Prescribers and telehealth platforms are about to learn which rules govern their January prescriptions, and the government will measure every prescription written this year and next against whichever rule applies.

The DEA and HHS telemedicine flexibilities for controlled substances run through December 31, 2026. Every no-visit prescription written under them will be judged by the rules in force when it was written.

Key Takeaways

• DEA and HHS telemedicine flexibilities for controlled substances expire December 31, 2026, so prescribing without an in-person visit needs a new legal footing in January.
• Absent a flexibility or registration, 21 U.S.C. § 829(e) governs, and prescribing outside 21 C.F.R. § 1306.04 can support a § 841 charge.
• DEA's January 2025 proposal would create three special registrations, including a first-ever registration for telemedicine platforms, plus state-by-state telemedicine registrations and fees.
• Florida prescribers and platforms should audit no-visit prescribing now, before agents in the Southern or Middle District of Florida ask for the records.
• The flexibilities relax only the in-person visit rule. They do not excuse a missing legitimate medical purpose or shorten the five-year limitations period.

What Changed and What Has Not

On December 31, 2025, DEA and HHS published a fourth temporary extension of the COVID-era telemedicine flexibilities. It allows a DEA-registered practitioner to prescribe Schedule II through V controlled substances by telemedicine without a prior in-person evaluation, if the prescription serves a legitimate medical purpose and other federal and state requirements are met. HHS announced it as running from January 1 through December 31, 2026.

The permanent fix has been pending since the Ryan Haight Act. DEA's January 2025 proposed rule (Docket DEA-407) would create a telemedicine prescribing registration for Schedule III through V, an advanced registration limited to certain specialists who may prescribe Schedule II through V, and a registration for telemedicine platforms, as DEA described at the time. It also contemplates state telemedicine registrations, a $888 fee for each special registration, electronic prescribing, and prescription drug monitoring checks. The proposal cites 21 U.S.C. § 802(54), § 829(e) and § 831(h).

Anyone who tells you today what the final rule requires is guessing, and counsel should say so plainly. Verify the review status on reginfo.gov before relying on any date.

What the Government Is Building

Controlled substance prescribing through telehealth was a growth business from 2020 forward, and prosecutors have spent those years learning how it works: the platform, the prescriber who signs, the pharmacy that fills, and the payer or patient who funds it. A year-end change in the rules gives investigators a clean way to frame the next set of cases. Expect agents to ask three questions of any no-visit prescription. What did the prescriber know about the patient? What did the platform tell the prescriber to do? Who profited from volume?

The platform, the prescriber who signs, the pharmacy that fills, and the payer or patient who funds it. Prosecutors have spent six years learning every link in that chain.

Platforms are the new focus. A registration category for platforms signals that DEA regards the company, not only the clinician, as part of the prescribing chain. A federal investigation that starts with a pharmacy or a prescriber often ends at the platform's order-entry software and its revenue model. The Done Global Adderall prosecution shows how far up that chain the government will go.

Exposure and Charges

The core charge is distribution under 21 U.S.C. § 841(a)(1). A practitioner's prescription is authorized only if issued for a legitimate medical purpose in the usual course of professional practice, the standard in 21 C.F.R. § 1306.04. The Supreme Court held in Ruan v. United States (2022) that once a prescriber produces evidence of authorization, the government must prove beyond a reasonable doubt that the prescriber knowingly or intentionally acted without authorization.

Group conduct brings 21 U.S.C. § 846 conspiracy, which carries the penalties of the underlying offense. When insurers pay, prosecutors add health care fraud under 18 U.S.C. § 1347 and conspiracy under 18 U.S.C. § 1349. Sentencing then turns on drug weight or loss, role, and whether the court finds a pattern of prescribing without examination. In a telehealth fraud investigation, loss and role are fought over spreadsheets, not witnesses.

In a telehealth fraud investigation, loss and role are fought over spreadsheets, not witnesses.

The five-year limitations period in 18 U.S.C. § 3282 matters here. A prescription written in March 2026 under the flexibilities remains chargeable into 2031. A new registration scheme does not erase it, and a future prosecutor will judge that prescription by the rules in force when it was written.

Florida Standard of Care and E-FORCSE Data

Florida adds its own layer. A prescriber is held to the standard of care under section 456.47, Florida Statutes, and Florida's prescription drug monitoring program, E-FORCSE under section 893.055, records nearly every controlled substance prescription dispensed in the state. The data reaches investigators before any subpoena does.

Mistakes Prescribers and Platforms Make Early

• Treating the extension as a safe harbor. It relaxes one requirement, the in-person visit. It leaves the legitimate medical purpose requirement untouched.
• Waiting for the final rule before reviewing current practice. Charging decisions look back, not forward.
• Editing charts or platform templates once an inquiry is foreseeable. Adding patient-specific reasoning to a closed record can become an obstruction count under 18 U.S.C. § 1519, a worse problem than the one you were fixing.
• Answering a DEA Diversion Investigator, a board investigator, or a federal agent without counsel. An explanation of a prescription is evidence of knowledge.

"Anyone who tells you today what the final rule requires is guessing, and counsel should say so plainly."— Aaron M. Cohen, AMC Defense Law

A Defense Approach That Works Before Charges

Begin with a privileged audit, directed by counsel, of a sample of no-visit controlled substance prescriptions. Sort them by schedule, by patient history, by whether a prior in-person visit exists, and by what the chart says in the prescriber's own words. The audit tells you whether you have a defensible clinical record, a documentation problem you can correct going forward, or exposure that should be addressed with the government on your terms.

If you have received a records request, a grand jury subpoena, or a letter from a U.S. Attorney's Office, the decision to cooperate, proffer, or litigate depends on what the data shows. A federal criminal defense attorney experienced in telemedicine fraud and DEA registration defense should make that call after the audit, not before. If the government wants a proffer session, an attorney should review the prescribing data first and open pre-charge negotiation with the AUSA from a position of knowledge.

Why Timing Matters Now

The regulatory change is the one thing this year with a known deadline. Charging decisions on 2025 and 2026 prescribing are still fluid. This is the period in which a white collar defense attorney can present clinical context and corrective action to the government before an indictment fixes the narrative. After charges, the same facts are argued to a jury.

Common Questions

Under Federal Investigation Over Telehealth Prescribing in Florida?

If you are under federal investigation, or your telehealth practice or platform has received a DEA records request, a federal grand jury subpoena, or a letter from a U.S. Attorney's Office, speak with a federal target letter attorney before you respond or change any records. If you want your no-visit prescribing reviewed before year-end, do it under privilege. AMC Defense Law, a Boca Raton federal criminal lawyer practice, handles federal investigation defense and South Florida healthcare fraud defense for prescribers, telehealth platforms, and practice owners in the Southern District of Florida, the Middle District of Florida, and nationwide. Consultations are confidential. Call 561.542.5494 or request a confidential consultation.

A privileged audit of no-visit prescribing, directed by counsel, tells a prescriber or platform where it stands before the government asks.

If you or your loved ones are under federal investigation over telehealth prescribing, call Aaron M. Cohen, 24 hours a day to get help.

About the author. Aaron M. Cohen is the founder and principal attorney of AMC Defense Law, a criminal defense firm in Boca Raton, Florida, with more than 30 years of experience in state and federal courts. He is admitted to practice in Florida, New York, New Jersey, and the District of Columbia, and before the United States District Courts for the Southern and Middle Districts of Florida, the Southern, Eastern, and Western Districts of New York, the District of New Jersey, and the Northern District of Texas. He appears pro hac vice in other federal districts nationwide. The firm represents clients in federal investigations and prosecutions involving healthcare fraud, Anti-Kickback Statute matters, DME and telemedicine fraud, peptide and compounded-drug enforcement, controlled-substance and drug conspiracy cases, financial crimes, and complex federal litigation, in Florida and nationwide.

This article is for general informational purposes only and is not legal advice. Reading it does not create an attorney-client relationship. Every matter turns on its own facts. The hiring of a lawyer is an important decision that should not be based solely upon advertisements. Prior results do not guarantee a similar outcome.